How I treat refractory acute GVHD

Area of Science:

• Immunology
• Transplantation Medicine
• Oncology

Background:

• Graft-versus-host disease (GVHD) significantly increases morbidity and mortality post-allogeneic hematopoietic cell transplantation (HCT).
• Primary therapy for acute GVHD typically involves glucocorticoids (steroids), but refractory cases present a therapeutic challenge.

Purpose of the Study:

• To review therapeutic approaches for steroid-refractory acute GVHD.
• To highlight the challenges in improving long-term survival and the critical role of infection prophylaxis.

Main Methods:

• Review of therapeutic strategies for steroid-refractory GVHD, including dose escalation, antibody therapies, immunotoxins, and other interventions.
• Analysis of outcomes from pilot studies regarding response rates and long-term survival.
• Emphasis on the high incidence of infectious complications as a major cause of treatment failure.

Main Results:

• Various therapeutic approaches have shown encouraging response rates in pilot studies.
• However, most studies did not demonstrate improved long-term survival compared to steroid monotherapy.
• High rates of severe infections (fungal, bacterial, viral) are a significant barrier to successful treatment.

Conclusions:

• Tailored therapy for steroid-refractory GVHD, considering time post-HCT, organ involvement, and severity, is appropriate.
• Intensive prophylaxis against infectious complications is crucial for all patients undergoing GVHD treatment.